Evidence map›Paper›PMID 39999857›Full record

ArticleFEMS microbiology ecology2025

Plipastatin is a shared good by Bacillus subtilis during combating Fusarium spp.

Rune Overlund Stannius, Ákos T Kovács

Abstract read
In one paragraph

Article in FEMS microbiology ecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rune Overlund StanniusDTU Bioengineering, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
Ákos T KovácsDTU Bioengineering, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.ORCID 0000-0002-4465-1636

Funding

Danish National Research Foundation DNRF137
6 · The paper itself

Abstract

Bacillus subtilis a Gram-positive soil-dwelling bacterium known for its wide range of bioactive secondary metabolites. The lipopeptide plipastatin produced by most B. subtilis isolates have been shown to exhibit potent antifungal activity against plant pathogenic fungi. While the effect of these antifungal compounds are well studied in the context of biocontrol, much less is known of their role in the environment, which also harbor nonproducing strains of these compounds. Fusarium species produce multiple antibacterial compounds resulting in dysbiosis of the plant-associated microbiome and inhibition of plant beneficial bacteria like B. subtilis. While plipastatin is expected to be important for survival of B. subtilis, not all isolates carry the biosynthetic gene cluster for plipastatin suggesting that the protective effect of plipastatin might be shared. In this study, we investigated the protective effect of plipastatin against Fusarium oxysporum in a coculture using a producer and a nonproducer isolate of plipastatin. We tested the survival of single and cocultured strains under Fusarium challenge in liquid media and solid agar plates to dissect the influence of spatial structure. Our results highlights that plipastatin protects the nonproducer strain in a density-dependent manner.

Indexed as

Antifungal AgentsBacillus subtilisFusariumOligopeptidesPeptides, CyclicFatty AcidsPlant DiseasesAntifungal AgentsFatty AcidsOligopeptidesPeptides, CyclicplipastatinBacillus subtilisFusarium oxysporumplipastatinpublic goodssecondary metabolite

Identifiers

PMID39999857
PMCPMC11916886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.